Monday March 18, 2:59 pm Eastern Time
Press Release
SOURCE: Perlegen
Philip N. Sussman Joins Perlegen Sciences, Inc. as Vice President of Business Development
MOUNTAIN VIEW, Calif.--(BW HealthWire)--March 18, 2002--Perlegen Sciences, Inc., a privately held genomics company, today announced a strategic appointment in the company's effort to commercialize its core technology. Philip N. Sussman joins Perlegen as Vice President of Business Development.
``A key part of Perlegen's business strategy is to establish relationships with pharmaceutical and biotechnology companies in order to associate genetic haplotypes with disease and drug response,'' said Brad Margus, CEO of Perlegen. ``Philip Sussman's experience in structuring alliances with pharmaceutical and biotechnology companies and his deep contacts within the business development community will be of great value to Perlegen in this regard.''
Mr. Sussman was previously a member of senior management at both public and private biotechnology companies, including SIGA Technologies, Inc., Memory Pharmaceuticals Corp., and Cadus Pharmaceutical Corporation. Prior to that he was Director of Strategy and Business Development at Ciba-Geigy Corp.'s (now Novartis') Pharmaceuticals Division.
Mr. Sussman is a member of the Review Panel for the Innovative Technology Research Grant Program, Center for Biotechnology, New York State Science and Technology Foundation. He is also author of recent articles in Scrip Magazine, The Journal of BioLaw & Business, and Journal of Commercial Biotechnology, where he is a member of the Editorial Board. He holds an S.M. in Management with a concentration in finance from the Sloan School of Management at the Massachusetts Institute of Technology, an M.S. degree in Biotechnology from Manhattan College, and a B.S. in Physics from the State University of New York at Stony Brook.
Formed in October, 2000 as a spin-off from Affymetrix, Inc., Perlegen Sciences, Inc. completed a $100 million private financing in March, 2001, and currently employs over 85 scientists, engineers, and business staff. The company uses high-density, whole-wafer microarray technology in combination with innovative approaches to sample preparation to look across the entire genome and cost effectively compare genetic variations between individuals. As it identifies the common patterns or ``haplotypes'' in which genetic variations occur, Perlegen develops tests to scan the DNA of thousands of individuals in order to associate genetic haplotypes with health and drug response. Perlegen also conducts downstream research aimed at elucidating the biology underlying those associations in order to accelerate the discovery of new drugs and the modification of existing treatments.
For business development inquiries, please contact Philip Sussman at bizdev@perlegen.com, or call (650) 625-4626. Information about Perlegen Sciences and its technologies can be found on Perlegen's web site perlegen.com. Perlegen is a trademark of Perlegen Sciences, Inc.
--------------------------------------------------------------------------------
Contact:
Perlegen Sciences, Inc.
Brad Margus, 650/625-4500 |
